

LA THANGUE et al  
Appl. No. 09/900,147  
July 26, 2006

RECEIVED  
CENTRAL FAX CENTER  
JUL 26 2006

**AMENDMENTS TO THE CLAIMS:**

Amend the claims as follows:

Claims 1-20. (Canceled)

21. (Previously Presented) An isolated polypeptide consisting of:

(i) a sequence consisting of the amino acid sequence

KNIRRRVYDALNVLAMNIIISKEKKEIKWIGLPTNSA (SEQ ID NO:1); or

(ii) a sequence consisting of the amino acid sequence

KNIRRRVYDALNVLAMNIIISKEKKEIKWIGLPTNSA (SEQ ID NO:1) and attached to 1 to 5 amino acid residues at the N- or C-terminus of SEQ ID NO:1, where the presence of said 1 to 5 amino acid residues has no significant effect on the function of the polypeptide.

22. (Currently Amended) An isolated polypeptide consisting of:

(i) the amino acid sequence of SEQ ID NO:2; or

(ii) the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6; or

(iii) the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6 joined to 1 to 5 amino acid residues at at least one of the N- or C-terminus of said SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:6, where the

LA THANGUE et al  
Appl. No. 09/900,147  
July 26, 2006

presence of said 1 to 5 amino acid residues has no significant effect on the function of the polypeptide, or

(iv) the amino acid sequence of SEQ ID NO:5 joined to 1 to 5 amino acid residues at the C-terminus of said SEQ ID NO:5, where the presence of said 1 to 5 amino acid residues has no significant effect on the function of the polypeptide,

which polypeptide is capable of antagonising the heterodimerisation of a DP protein with an E2F protein.

~~a fragment of a sequence consisting of the amino acid sequence  
KNIRRRVYDALNVLAMMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), and from 1 to 5  
amino acid residues joined to at least one of the N or C terminus of the fragment,  
where the presence of the 1 to 5 amino acid residues has no significant effect on the  
function of the polypeptide;~~

~~which polypeptide is capable of antagonising the heterodimerisation of a DP  
protein with an E2F protein.~~

Claims 23-24. (Canceled)

25. (Previously Presented) An isolated variant of a polypeptide consisting of:

(i) a sequence consisting of the amino acid sequence

KNIRRRVYDALNVLAMMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), or

LA THANGUE et al  
Appl. No. 09/900,147  
July 26, 2006

(ii) a sequence consisting of the amino acid sequence  
KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1) attached to 1 to 5  
amino acid residues at the N- or C-terminus of SEQ ID NO:1, where the presence of  
said 1 to 5 amino acid residues has no significant effect on the function of the  
polypeptide;

said variant differing from the polypeptide by the presence of from 1 to 5 amino  
acid substitutions in the sequence of said polypeptide, said variant being capable of  
antagonising the heterodimerisation of a DP protein with an E2F protein.

26. (Previously Presented) The variant according to claim 25 wherein the  
substitutions include substitutions selected from one or more residues corresponding to  
residues 167, 169, 171 and 175 of DP-1.

27. (Previously Presented) An isolated polypeptide consisting of an amino  
acid sequence (i) attached to an amino acid sequence (ii) wherein said amino acid  
sequence (ii) is attached to the N- or C- terminus of said amino acid sequence (i),

said amino acid sequence (i) consisting of an amino acid sequence selected from  
the group consisting of:

- (a) KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1),
- (b) NVLMAMNII (SEQ ID NO:2),
- (c) RRRVYDALNVLMAMNIISK (SEQ ID NO:3),

LA THANGUE et al  
Appl. No. 09/900,147  
July 26, 2006

- (d) NVLMAMNIISKEKKEIKWIG (SEQ ID NO:4),
- (e) RVYDALNVLMAMNIIS (SEQ ID NO:5),
- (f) YDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:6), and
- (g) ALNVLMA (SEQ ID NO:7); and

said amino acid sequence (ii) consisting of a sequence of amino acids not naturally contiguous to said amino sequence (i).

28. (Previously Presented) A polypeptide according to claim 27 wherein the amino acid sequence (ii) is a membrane translocation sequence.

29. (Previously Presented) A polypeptide according to claim 28 wherein the membrane translocation sequence is a membrane translocation sequence of the *Drosophila melanogaster* antennapedia protein.

30. (Previously Presented) A composition comprising a polypeptide according to any one of claims 21 to 29 together with a pharmaceutically acceptable diluent or carrier.

31. (Previously Presented) A composition according to claim 30 which further comprises a cytostatic or cytotoxic agent.

32. (Previously Presented) A composition formulation comprising a polypeptide of SEQ ID NO:1 in the form of an orally, topically or parenterally administrable form.

LA THANGUE et al  
Appl. No. 09/900,147  
July 26, 2006

Claims 33-35. (Canceled)

36. (Previously Presented) An isolated product comprising a polypeptide consisting of:

(i) a sequence consisting of the amino acid sequence  
KNIRRRVYDALNVLAMNIIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), or

(ii) a sequence consisting of the amino acid sequence  
KNIRRRVYDALNVLAMNIIISKEKKEIKWIGLPTNSA (SEQ ID NO:1) attached to 1 to 5 amino acid residues at the N- or C-terminus of SEQ ID NO:1, where the presence of the 1 to 5 amino acid residues has no significant effect on the function of the polypeptide;

and a cytostatic or cytotoxic agent as a combined preparation.

Claim 37. (Canceled)